Day: May 3, 2017

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Adverse Effect Reporting System. The results of the examination of population scale data...

MORE

Popular Blog Posts

The Denver Post features Transcendent Ketamine of Colorado & Boulder Mind Care December 24 2023

The Pandemic, Teen Depression, and Suicide Risk

Measures to contain the spread of coronavirus have inadvertently increased teen depression and suicide risk, as demonstrated by Mayne…

LEARN MORE

Ketamine Infusion Therapy for PTSD – Results of an Important New Study

A recent study[1] published in the January 5, 2021 American Journal of Psychiatry by Dr. Adriana Feder and her…

LEARN MORE

Ketamine – The Most Powerful Treatment For Depression Yet Invented

Ketamine continues to gain recognition, by both lay public and medical professionals, as a remarkably effective antidepressant, with minimal…

LEARN MORE

Coronavirus Anxiety Syndrome

Many of our ketamine therapy patients tell us that the COVID-19 pandemic is causing a dramatic increase in their…

LEARN MORE

FDA Approval Expected Monday of Ketamine-derived “Spravato”

      TAKE HOME POINTS: SpravatoTM, a form of ketamine, will be FDA approved on Monday for Treatment…

LEARN MORE